Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment
Interview: There is a critical need for more effective therapies, as current treatment strategies still fall short of achieving long-term disease control in a substantial proportion of patients.
In this interview, Dr. Andrea Lenartova, senior hematologist at Oslo University Hospital and specialist in AML, shares her insights into the newly approved therapy.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen